Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06911424 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
A Phase 3 study of Bacterial Conjunctivitis, sponsored by Baxis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06911424: Recruiting Phase 3 study of Bacterial Conjunctivitis, sponsored by Baxis Pharmaceuticals.
NCT06911424 is a Phase 3 study of Bacterial Conjunctivitis that is actively recruiting participants, run by Baxis Pharmaceuticals. The registered enrollment target is 400 participants, below the 568-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06911424, a Phase 3 study of Bacterial Conjunctivitis, is actively recruiting participants, sponsored by Baxis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
Primary Outcome
Proportion of patients with a positive bacterial culture at Visit 1 (Day 1) who achieve clinical cure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fusidic Acid 1%
Study Locations (20)
Florida
- Baxis Site 34 - Delray Beach
- Baxis Site 22 - Doral
- Baxis Site 11 - Lake Worth
- Baxis Site 37 - Largo
- Baxis Site 27 - Lutz
- Baxis Site 01 - Miami
- Baxis Site 03 - Miami
- Baxis Site 13 - Miami Beach
- Baxis Site 28 - Miami Lakes
- Baxis Site 29 - Palm Springs
- Baxis Site 10 - Tampa
California
- Baxis Site 24 - Huntington Beach
- Baxis Site 19 - La Jolla
- Baxis Site 39 - Long Beach
- Baxis Site 31 - Los Angeles
- Baxis Site 38 - Los Angeles
- Baxis Site 20 - Sherman Oaks
Arkansas
- Baxis Site 04 - Little Rock
Georgia
- Baxis Site 35 - Union City
Idaho
- Baxis Site 15 - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2026-03-23 |
| Phase | Phase 3 |
What NCT06911424 shows while recruiting
NCT06911424 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 568-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06911424 names 20 study sites across 5 states, led by Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06911424 about?
NCT06911424 is a clinical study titled "Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis". The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
What is the current status of trial NCT06911424?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-03-21. Estimated completion is 2026-03-23.
What conditions does trial NCT06911424 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis.
What interventions are being tested in trial NCT06911424?
The interventions under investigation include: Placebo (DRUG), Fusidic Acid 1% (DRUG).
Who is sponsoring clinical trial NCT06911424?
This trial is sponsored by Baxis Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06911424 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
COMPLETED · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
COMPLETED · Phase 3
-
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI